These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 11678835

  • 1. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
    Siddiqi A, Foley RR, Britton KE, Sibtain A, Plowman PN, Grossman AB, Monson JP, Besser GM.
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
    [Abstract] [Full Text] [Related]

  • 2. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS.
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [Abstract] [Full Text] [Related]

  • 3. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF, Oei HY, Hennemann G, Krenning EP.
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
    Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, Clerc J.
    Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
    [Abstract] [Full Text] [Related]

  • 6. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL, Rodríguez Rodríguez JR, Borrego Dorado I, Navarro González E, Tirado Hospital JL, Vázquez Albertino R.
    Rev Esp Med Nucl; 2007 Mar; 26(3):138-45. PubMed ID: 17524307
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
    Oyen WJ, Verhagen C, Saris E, van den Broek WJ, Pieters GF, Corsten FH.
    J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre.
    Giovanni V, Arianna LG, Antonio C, Francesco F, Michele K, Giovanni S, Marco S, Giovanni L.
    Clin Endocrinol (Oxf); 2002 Feb; 56(2):247-52. PubMed ID: 11874417
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy.
    Ali N, Sebastian C, Foley RR, Murray I, Canizales AL, Jenkins PJ, Drake WM, Plowman PN, Besser GM, Chew SL, Grossman AB, Monson JP, Britton KE.
    Nucl Med Commun; 2006 Feb; 27(2):165-9. PubMed ID: 16404230
    [Abstract] [Full Text] [Related]

  • 14. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement.
    Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, Mandel SJ.
    Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1012-7. PubMed ID: 17256140
    [Abstract] [Full Text] [Related]

  • 15. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.
    Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J.
    J Clin Endocrinol Metab; 1995 May; 80(5):1488-92. PubMed ID: 7744991
    [Abstract] [Full Text] [Related]

  • 16. Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma.
    Lindegaard MW, Paus E, Høie J, Kullman G, Stenwig AE.
    Acta Chir Scand; 1988 Feb; 154(2):141-5. PubMed ID: 3354295
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
    Bajén MT, Mañé S, Muñoz A, García JR.
    J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
    [Abstract] [Full Text] [Related]

  • 19. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M, Perotti G, Rufini V, Maussier ML, Dottorini M.
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [Abstract] [Full Text] [Related]

  • 20. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
    Ringel MD, Balducci-Silano PL, Anderson JS, Spencer CA, Silverman J, Sparling YH, Francis GL, Burman KD, Wartofsky L, Ladenson PW, Levine MA, Tuttle RM.
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.